VERAXA Biotech AG (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG. The company will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. This milestone marks a significant step for the company as it advances its pipeline of bispecific T-cell engagers and antibody-drug conjugates (ADCs) based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.
According to the company, proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support the advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate. This data highlights the potential of the BiTAC platform to address key challenges in cancer therapy, such as on-target off-tumor toxicity.
The business combination is expected to provide VERAXA with the necessary capital and public market presence to accelerate its research and development efforts. The BiTAC platform, which integrates bispecific T-cell engagers with ADC technology, aims to improve therapeutic index and patient outcomes. With the completion of this transaction, VERAXA is positioned to advance its pipeline toward clinical trials, potentially offering new treatment options for patients with solid tumors and hematologic malignancies.
For investors and the biotech industry, this development underscores the growing interest in next-generation antibody-based therapeutics. The successful listing on Nasdaq provides VERAXA with access to public capital markets, which could facilitate further funding and partnerships. For more information on the business combination, visit the full press release at https://ibn.fm/ka00j.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T-cell engagers, bispecific ADCs, and other innovative formats. For regular updates about VERAXA Biotech, visit www.veraxa.com.
Voyager Acquisition Corp., the special purpose acquisition company that merged with VERAXA, aims to revolutionize the healthcare sector through strategic combinations. With a team of experienced executives in investing, operations, and medical innovation, Voyager seeks to scale companies to new heights. More information is available at https://www.voyageracq.com.
The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
